CO4900070A1 - NUEVOS DERIVADOS DE ACIDO CARBONICO, SU PRODUCCION Y APLICA- CION COMO ANTAGONISTAS MIXTOS DE RECEPTORES ET(sub A)/ET- (sub B) - Google Patents
NUEVOS DERIVADOS DE ACIDO CARBONICO, SU PRODUCCION Y APLICA- CION COMO ANTAGONISTAS MIXTOS DE RECEPTORES ET(sub A)/ET- (sub B)Info
- Publication number
- CO4900070A1 CO4900070A1 CO97051479A CO97051479A CO4900070A1 CO 4900070 A1 CO4900070 A1 CO 4900070A1 CO 97051479 A CO97051479 A CO 97051479A CO 97051479 A CO97051479 A CO 97051479A CO 4900070 A1 CO4900070 A1 CO 4900070A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- substituted
- phenyl
- alkenyl
- cycloalkyl
- Prior art date
Links
- 150000004649 carbonic acid derivatives Chemical class 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 8
- 229910052757 nitrogen Inorganic materials 0.000 abstract 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 6
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 4
- 150000002431 hydrogen Chemical class 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 239000011593 sulfur Chemical group 0.000 abstract 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 abstract 3
- 125000001624 naphthyl group Chemical group 0.000 abstract 3
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 abstract 2
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 abstract 2
- 125000002947 alkylene group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 150000001768 cations Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 abstract 1
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 229910052783 alkali metal Inorganic materials 0.000 abstract 1
- 150000001340 alkali metals Chemical class 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 abstract 1
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 abstract 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- -1 hydrozi Inorganic materials 0.000 abstract 1
- 229910052751 metal Inorganic materials 0.000 abstract 1
- 239000002184 metal Substances 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
- 150000003536 tetrazoles Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Derivados de ácido carbónico de la fórmula I:CARACTERIZADOS porqueR1 significa tetrazol o a un grupo en el que R tiene el siguiente significado: a) un residuo OR7 , en donde R7 significa: hidrógeno, el catión de un metal alcalino, el catión de un metal alcalinotérreo, o un ión amonio fisiológicamente compatible;C3 -C8 cicloalquilo, C1 -C8 alquilo, CH2 -fenilo, que puede ser sustituido Un C3 -C6 -alquenilo o un grupo C3 -C6 -alquinilo, que puede ser sustituido o fenilo, en caso dado, sustituido. b) un heteroaromato de 5 eslabones ligado con un átomo de nitrógeno, c) un grupo en el que k toma los valores 0, 1 y 2, p los calores 1, 2, 3 y 4 y R8 representa C1 -C4 -alquilo, - 2 -C3 -C8 -cicloalquilo, C3 -C6 -alquenilo, C3 -C6-alquinilo o fenilo, que puede ser sustituido d) un residuo en el que R9 significa: C1 -C4 -alquilo, C3 -C6 -alquenilo, C3 -C6 -alquinilo, C3 -C8 -cicloalquilo, donde estos residuos pueden tener un residuo C1 -C4 -alcoxi, C1 -C4 -alquiltio y/o un residuo de fenilo fenilo en caso de ser necesario sustituido e) un residuo.en donde R13 y R14 pueden ser iguales o diferentes y tienen el siguiente significado: hidrógeno, C1 -C8 -alquilo, C3 -C8 -cicloalquilo, C3 -C8 -alquenilo, C3 -C8 -alquinilo, bencilo, fenilo que puede ser sustituido o R13 y R14 forman juntos una cadena C4 -C7 -alquileno cerrada la cual puede ser sustituida, que, puede contener un heteroátomo R2 hidrógeno, hidrozi, NH2 NH(C1 -C4 -alquilo), N(C1 -C4 -alquilo)2 , halógeno, C1 -C4 -alquilo, C2 -C4 -alquenilo, C2 -C4 -alquinilo, C1 -C4 -hidroxialquilo, C1 -C4 -alquilo halógeno, C1 -C4 -alcoxi, C1 -C4 -alcoxi halógeno o C1 -C4 -alquiltio, o CR2 está unido con CR10 como se indica abajo en un anillo de 5 a 6 eslabonesX nitrógeno o metilo. Y nitrógeno o metilo Z nitrógeno o CR10 , en donde CR10 significa hidrógeno o C1 -C4 -alquilo o CR10 junto con CR2 o CR3 forma un anillo de alquileno de 5 o 6 eslabones o de alquenilo, que puede ser sustituido y en donde uno o más grupos metilenos pueden ser sustituidos por oxígeno, azufre - NH o N(C1 -C4 -alquilo) R3 hidrógeno, hidroxi, NH2 , NH (C1 -C4 -alquilo), N(C1 -C4 -alquilo)2 , halógeno, C1 -C4 -alquilo, C2 -C4 -alquenilo, C2 -C4 -alquinilo, C1 -C4 -alquilo halógeno, C1 -C4 -alcoxi, C1 -C4 -alcoxi halógeno, C1 -C4 -alquiltio o CR3 está unido con CR10 tal como se indica arriba en un anillo de 5 o 6 eslabones. R4 y R5 (que pueden ser iguales o distintos): fenilo o naftilo, que pueden ser sustituidos, o fenilo o naftilo, que pueden estar unidos en posición orto por una unión directa a un grupo metileno, etileno o etenileno, a un átomo de oxígeno o azufre o a un grupo SO2 , NHAND#8209; o NAND#8209;alquilo; C3 AND#8209;C8 AND#8209;cicloalquilo, en caso necesario, sustituido R6 en caso necesario C3 AND#8209;C8 AND#8209;cicloalquilo sustituido fenilo o naftilo, que pueden ser sustituidos en heteroaromato de cinco a seis eslabones conteniendo de uno a tres átomos de nitrógeno y/o átomo de azufre u oxígeno, que puede ser sustituidoW azufre y oxígenoQ Un distanciador que en su largo corresponda a una cadena C2 AND#8209;C4 . así como las sales fisiológicamente compatibles y las formas enantiómeras y diastereómeras.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19636046A DE19636046A1 (de) | 1996-09-05 | 1996-09-05 | Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO4900070A1 true CO4900070A1 (es) | 2000-03-27 |
Family
ID=7804712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO97051479A CO4900070A1 (es) | 1996-09-05 | 1997-09-04 | NUEVOS DERIVADOS DE ACIDO CARBONICO, SU PRODUCCION Y APLICA- CION COMO ANTAGONISTAS MIXTOS DE RECEPTORES ET(sub A)/ET- (sub B) |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6670367B1 (es) |
| EP (1) | EP0929529A2 (es) |
| JP (1) | JP2000517329A (es) |
| KR (1) | KR20000068446A (es) |
| CN (1) | CN1236362A (es) |
| AR (1) | AR009543A1 (es) |
| AU (1) | AU736414B2 (es) |
| BG (1) | BG103258A (es) |
| BR (1) | BR9711693A (es) |
| CA (1) | CA2265504A1 (es) |
| CO (1) | CO4900070A1 (es) |
| DE (1) | DE19636046A1 (es) |
| HU (1) | HUP0000664A3 (es) |
| ID (1) | ID19417A (es) |
| IL (1) | IL128743A0 (es) |
| NO (1) | NO312674B1 (es) |
| NZ (1) | NZ334548A (es) |
| PL (1) | PL331998A1 (es) |
| SK (1) | SK25999A3 (es) |
| TR (1) | TR199900486T2 (es) |
| WO (1) | WO1998009953A2 (es) |
| ZA (1) | ZA977946B (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6030975A (en) * | 1997-03-14 | 2000-02-29 | Basf Aktiengesellschaft | Carboxylic acid derivatives, their preparation and use in treating cancer |
| CN1269792A (zh) * | 1997-09-04 | 2000-10-11 | Basf公司 | 新羧酸衍生物,它们的制备方法和作为混合eta/etb受体拮抗药的用途 |
| DE59810600D1 (de) * | 1997-09-26 | 2004-02-19 | Abbott Gmbh & Co Kg | Endothelin antagonist und renin-angiotensin system hemmer als kombinationspräparate |
| DE19743143A1 (de) * | 1997-09-30 | 1999-04-01 | Knoll Ag | Pharmazeutische Kombinationspräparate |
| AU742506B2 (en) * | 1997-10-17 | 2002-01-03 | Eurogene Limited | The use of inhibitors of the renin-angiotensin system |
| DE19809144A1 (de) * | 1998-03-04 | 1999-09-09 | Basf Ag | Neue unsymmetrisch substituierte Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶LAMBDA¶/ET¶B¶-Rezeptorantagonisten |
| DE19836044A1 (de) * | 1998-08-10 | 2000-02-17 | Basf Ag | Neue Carbonsäurederivate, die Ketoseitenketten tragen, ihre Herstellung und Verwendung als Endothelin-Rezeptorantagonisten |
| US7566452B1 (en) | 1999-05-04 | 2009-07-28 | New York University | Cancer treatment with endothelin receptor antagonists |
| DE19933164A1 (de) * | 1999-07-20 | 2001-01-25 | Basf Ag | Neue Carbonsäurederivate mit 5,6 substituiertem Pyrimidinring, ihre Herstellung und Verwendung als Endothelin Rezeptorantagonisten |
| DE19951671A1 (de) * | 1999-10-27 | 2001-05-03 | Basf Ag | 2-(4,6-Dimethyl-pyrimidin-2-yloxy)-3-(2-(3,4-dimethoxyphenyl)ethoxy)-3,3-diphenylpropionssäure-Natriumsalz und seine Verwendung als Endothelinantagonist |
| DE10064797A1 (de) * | 2000-12-22 | 2002-06-27 | Knoll Ag | Orale und parenterale pharmazeutische Formulierung, umfassend eine niedermolekulare Thrombininhibitor-Pro-Pharmakon |
| JP4155561B2 (ja) * | 2000-12-26 | 2008-09-24 | 国立大学法人佐賀大学 | アレルギー性疾患検査方法 |
| PT1243262E (pt) | 2001-03-20 | 2006-10-31 | Sanol Arznei Schwarz Gmbh | Nova utilizacao de uma classe de compostos peptideos para o tratamento da dor inflamatoria nao neuropatica |
| DK1243263T3 (da) | 2001-03-21 | 2003-03-17 | Sanol Arznei Schwarz Gmbh | Hidtil ukendt anvendelse af en klasse af peptidforbindelser til behandling af allodyni eller andre forskellige typer af kronisk- eller fantomsmerte |
| CN1950101B (zh) | 2004-04-16 | 2011-03-30 | 舒沃茨药物股份公司 | 肽化合物用于预防和治疗慢性头痛的用途 |
| EP1604656A1 (en) | 2004-06-09 | 2005-12-14 | Schwarz Pharma Ag | Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS) |
| KR20070045271A (ko) | 2004-08-27 | 2007-05-02 | 쉬바르츠파르마에이지 | 골암 통증, 화학요법- 및 뉴클레오시드- 유도 통증의치료를 위한 펩티드 화합물의 용도 |
| CA2646438A1 (en) * | 2006-03-13 | 2007-09-20 | Encysive Pharmaceuticals, Inc. | Methods and compositions for treatment of diastolic heart failure |
| AU2007225207A1 (en) * | 2006-03-13 | 2007-09-20 | Encysive Pharmaceuticals, Inc. | Formulations of sitaxsentan sodium |
| EP2992891B1 (en) | 2006-06-15 | 2020-08-05 | UCB Pharma GmbH | Pharmaceutical composition comprising brivaracetam and lacosamide with synergistic anticonvulsant effect |
| US20080026061A1 (en) * | 2006-06-22 | 2008-01-31 | Reichwein John F | Crystalline N-(4-chloro-3-methyl-5-isoxazolyl)-2-[2-methyl-4.5-(methylenedioxy)phenylacetyl]-thiophene-3-sulfonamide |
| CN103709106A (zh) * | 2013-12-06 | 2014-04-09 | 石家庄博策生物科技有限公司 | 一种立体选择性制备安立生坦的方法 |
| CN103739557B (zh) * | 2013-12-30 | 2015-10-21 | 黄河三角洲京博化工研究院有限公司 | 一种4,6-二甲基-2-甲磺酰基嘧啶的合成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4313412A1 (de) * | 1993-04-23 | 1994-10-27 | Basf Ag | 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung |
| DE4313413A1 (de) * | 1993-04-23 | 1994-10-27 | Basf Ag | 3-(Het)aryloxy(thio)-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung |
| DE4335950A1 (de) | 1993-10-21 | 1995-04-27 | Basf Ag | Derivate von 3-Hydroxycarbonsäuren, deren Herstellung und Verwendung |
| DE4411225A1 (de) | 1994-03-31 | 1995-10-05 | Basf Ag | Verwendung von Carbonsäurederivaten als Arzneimittel |
| DE19533023B4 (de) * | 1994-10-14 | 2007-05-16 | Basf Ag | Neue Carbonsäurederivate, ihre Herstellung und Verwendung |
| DE19536891A1 (de) | 1995-10-04 | 1997-04-10 | Basf Ag | Neue Aminosäurederivate, ihre Herstellung und Verwendung |
-
1996
- 1996-09-05 DE DE19636046A patent/DE19636046A1/de not_active Withdrawn
-
1997
- 1997-03-02 US US09/254,137 patent/US6670367B1/en not_active Expired - Fee Related
- 1997-09-02 BR BR9711693A patent/BR9711693A/pt not_active IP Right Cessation
- 1997-09-02 JP JP10512203A patent/JP2000517329A/ja active Pending
- 1997-09-02 HU HU0000664A patent/HUP0000664A3/hu unknown
- 1997-09-02 CN CN97199458A patent/CN1236362A/zh active Pending
- 1997-09-02 NZ NZ334548A patent/NZ334548A/xx unknown
- 1997-09-02 PL PL97331998A patent/PL331998A1/xx unknown
- 1997-09-02 AU AU45524/97A patent/AU736414B2/en not_active Ceased
- 1997-09-02 TR TR1999/00486T patent/TR199900486T2/xx unknown
- 1997-09-02 IL IL12874397A patent/IL128743A0/xx unknown
- 1997-09-02 KR KR1019997001815A patent/KR20000068446A/ko not_active Ceased
- 1997-09-02 WO PCT/EP1997/004688 patent/WO1998009953A2/de not_active Ceased
- 1997-09-02 CA CA002265504A patent/CA2265504A1/en not_active Abandoned
- 1997-09-02 EP EP97943819A patent/EP0929529A2/de not_active Withdrawn
- 1997-09-02 SK SK259-99A patent/SK25999A3/sk unknown
- 1997-09-04 CO CO97051479A patent/CO4900070A1/es unknown
- 1997-09-04 ZA ZA977946A patent/ZA977946B/xx unknown
- 1997-09-05 AR ARP970104059A patent/AR009543A1/es not_active Application Discontinuation
- 1997-09-05 ID IDP973110A patent/ID19417A/id unknown
-
1999
- 1999-03-04 NO NO19991079A patent/NO312674B1/no not_active IP Right Cessation
- 1999-03-16 BG BG103258A patent/BG103258A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL128743A0 (en) | 2000-01-31 |
| CA2265504A1 (en) | 1998-03-12 |
| NO991079L (no) | 1999-05-04 |
| NO312674B1 (no) | 2002-06-17 |
| NO991079D0 (no) | 1999-03-04 |
| NZ334548A (en) | 2000-09-29 |
| BG103258A (en) | 2000-12-29 |
| SK25999A3 (en) | 1999-09-10 |
| DE19636046A1 (de) | 1998-03-12 |
| WO1998009953A2 (de) | 1998-03-12 |
| AU736414B2 (en) | 2001-07-26 |
| HUP0000664A3 (en) | 2001-07-30 |
| PL331998A1 (en) | 1999-08-16 |
| AR009543A1 (es) | 2000-04-26 |
| CN1236362A (zh) | 1999-11-24 |
| ZA977946B (en) | 1999-03-04 |
| KR20000068446A (ko) | 2000-11-25 |
| ID19417A (id) | 1998-07-09 |
| TR199900486T2 (xx) | 1999-06-21 |
| WO1998009953A3 (de) | 1998-10-29 |
| JP2000517329A (ja) | 2000-12-26 |
| HUP0000664A2 (hu) | 2001-04-28 |
| US6670367B1 (en) | 2003-12-30 |
| AU4552497A (en) | 1998-03-26 |
| EP0929529A2 (de) | 1999-07-21 |
| BR9711693A (pt) | 1999-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4900070A1 (es) | NUEVOS DERIVADOS DE ACIDO CARBONICO, SU PRODUCCION Y APLICA- CION COMO ANTAGONISTAS MIXTOS DE RECEPTORES ET(sub A)/ET- (sub B) | |
| AR076228A1 (es) | Piperidinas sustituidas como antagonistas de ccr3 | |
| CR7865A (es) | Derivados de dihidropiranoindol -3,4-diona sustituidos y derivados de 2-hidroximetilindol del acido 3-oxoacetico sustituidos como inhibidores del inhibidor del activador del plasminogeno 1(pai-1) | |
| ES2135543T3 (es) | Piperidinas (4-aril-sustituidas) como antagonistas de los receptores de neuroquininas. | |
| AR064731A1 (es) | Derivados de 2,4-dianilinopirimidinas, su preparacion, composiciones farmaceuticas y usos como inhibidores de ikk | |
| ES2137998T3 (es) | Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos. | |
| EA200100755A1 (ru) | 4-оксо-1,4-дигидро-3-хинолинкарбоксамиды как антивирусные агенты | |
| UY28823A1 (es) | Compuestos de ácido alfa aril o heteroaril metil beta piperidino propanoico como antagonistas del receptor orl1 | |
| CO5070570A1 (es) | DERIVADOS DE TIROSINA COMO ACTIVADORES DE hPPAR Y hPPARalfa Y UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE | |
| CO5640049A2 (es) | Inhibidores de fluor y trifluoroalquilo que contienen inhibidores de sulfonamieda heterociclicos de la produccion beta amiloide y derivados de los mismos | |
| CO5680403A2 (es) | Antagonistas de mchr1r | |
| AR029216A1 (es) | Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento | |
| ES2113927T3 (es) | Compuestos utiles como antagonistas de leucotrienos. | |
| ES2039242T3 (es) | Un procedimiento para la preparacion de nuevos derivados de piperidina. | |
| ATE273305T1 (de) | Thrombin-inhibitoren | |
| AR034268A1 (es) | Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion | |
| CO5630034A2 (es) | Procedimiento y composiciones farmaceuticas para tratar aterosclerosis, dislipidemias y afecciones relacionadas | |
| CO5611152A2 (es) | Compuestos derivados piperidina caracterizados por ser antagonistas del receptor de las taquicininas, especialmente del receptor nk1 y composiciones farmaceuticas que los contienen | |
| ES2086341T3 (es) | Derivados de aminoacidos con propiedades inhibidoras de la renina, procedimiento para su preparacion, agentes que los contienen y su utilizacion. | |
| CO4900040A1 (es) | Nuevos derivados de acidos alfa-hidroxi su preparacion y aplicacion | |
| AR052915A1 (es) | Derivados de pirrolidin y piperidin acetileno | |
| CO4930270A1 (es) | Derivados heterociclicos de acido carbonico su produccion y aplicacion como antagonistas de receptores deendotelina | |
| PE46599A1 (es) | Metodo de uso de carbamatos y ureas neurotropicos | |
| ES2138594T3 (es) | Agentes derivados de piridina e imidazol para enfermedades cardiovasculares. | |
| CO4950605A1 (es) | Nuevos derivados b-amino y b-azido de acido carbonico, su produccion y aplicacion como antagonistas de receptores de endotelina |